Effect of systemic iron overload and a chelation therapy in a mouse model of the neurodegenerative disease hereditary ferritinopathy

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Garringer, Holly J ^a   Irimia, Jose M ^a   Li, Wei ^a   Goodwin, Charles B ^a   Richine, Briana ^a   Acton, Anthony ^a   Chan, Rebecca J ^a   Peacock, Munro ^a   Muhoberac, Barry B ^b   Ghetti, Bernardino ^a   Vidal, Ruben ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; FERRITIN; IRON; PLACEBO; APOFERRITIN; FTL PROTEIN, HUMAN; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; FIBROBLAST; HEREDITARY FERRITINOPATHY; IN VIVO STUDY; IRON BALANCE; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; ANIMAL; CELL CULTURE; CHELATION THERAPY; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; HUMAN; IRON METABOLISM DISORDERS; METABOLISM; NEUROAXONAL DYSTROPHIES;

ANIMALS; APOFERRITINS; CELL SURVIVAL; CELLS, CULTURED; CHELATION THERAPY; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; HUMANS; IRON; IRON CHELATING AGENTS; IRON METABOLISM DISORDERS; IRON OVERLOAD; MALE; MICE; NEUROAXONAL DYSTROPHIES; OXIDATIVE STRESS; PYRIDONES;

EID: 84990223939     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161341     Document Type: Article

References (27)

1. Muhoberac BB, Vidal R (2013) Abnormal iron homeostasis and neurodegeneration. Front Aging Neurosci 5:32. doi: 10.3389/fnagi.2013.00032 PMID: 23908629
2. Chinnery PF, Crompton DE, Birchall D, Jackson MJ, Coulthard A, Lombès A, et al. (2007) Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 130, 110-19. PMID: 17142829
3. Vidal R, Ghetti B (2015) Hereditary Ferritinopathies. In: Neuropathology of Neurodegenerative Diseases: A Practical Guide (Kovacs G, ed), 15:263-267. Cambridge University Press.
4. Vidal R, Ghetti B, Takao M, Brefel-Courbon C, Uro-Coste E, Glazier BS, et al. (2004) Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J. Neuropathol. Exp. Neurol. 63, 363-380. PMID: 15099026
5. Baraibar MA, Barbeito AG, Muhoberac BB, Vidal R (2008) Iron-mediated aggregation and a localized structural change characterize ferritin from a mutant light chain polypeptide that causes neurodegeneration. J. Biol. Chem. 283, 31679-31689. doi: 10.1074/jbc.M805532200 PMID: 18755684
6. Baraibar MA, Muhoberac BB, Garringer HJ, Hurley TD, Vidal R (2010) Unraveling of the E helices and disruption of 4-fold pores are associated with iron mishandling in a mutant ferritin causing neurodegeneration. J. Biol. Chem. 285, 1950-1956. doi: 10.1074/jbc.M109.042986 PMID: 19923220
7. Baraibar MA, Barbeito AG, Muhoberac BB, Vidal R (2012) A mutant light-chain ferritin that causes neurodegeneration has enhanced propensity toward oxidative damage. Free Radic Biol Med. 52, 1692-1697. doi: 10.1016/j.freeradbiomed.2012.02.015 PMID: 22348978
8. Muhoberac BB, Baraibar MA, Vidal R (2010) Iron loading-induced aggregation and reduction of iron incorporation in heteropolymeric ferritin containing a mutant light chain that causes neurodegeneration. Biochim. Biophys. Acta. 1812, 544-548. doi: 10.1016/j.bbadis.2010.10.010 PMID: 21029774
9. Kubota A, Hida A, Ichikawa Y, Momose Y, Goto J, Igeta Y, et al. (2009) A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations. Mov. Disord. 24, 441-445. doi: 10.1002/mds.22435 PMID: 19117339
10. Vidal R, Miravalle L, Gao X, Barbeito AG, Baraibar MA, Hekmatyar SK, et al. (2008) Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice. J. Neurosci. 28, 60-67 doi: 10.1523/JNEUROSCI.3962-07.2008 PMID: 18171923
11. Barbeito AG, Garringer HJ, Baraibar MA, Gao X, Arredondo M, Núñez MT, et al. (2009) Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene. J. Neurochem. 109, 1067-1078. doi: 10.1111/j.1471-4159.2009.06028.x PMID: 19519778
12. Deng X, Vidal R, Englander EW (2010) Accumulation of oxidative DNA damage in brain mitochondria in mouse model of hereditary ferritinopathy. Neurosci Lett. 479(1):44-8. doi: 10.1016/j.neulet.2010.05.025 PMID: 20478358
13. Schuermann M (1990) An expression vector system for stable expression of oncogenes. Nucleic Acids Res. 18(16):4945-6. PMID: 2395667
14. Jia CH, Li M, Liu J, Zhao L, Lin J, Lai PL, et al. (2013) IKK-β mediates hydrogen peroxide induced cell death through p85 S6K1. Cell Death Differ. 20(2):248-58. doi: 10.1038/cdd.2012.115 PMID: 22955948
15. Dev S, Kumari S, Singh N, Kumar Bal S, Seth P, Mukhopadhyay CK (2015) Role of extracellular Hydrogen peroxide in regulation of iron homeostasis genes in neuronal cells: Implication in iron accumulation. Free Radic Biol Med. 86:78-89. doi: 10.1016/j.freeradbiomed.2015.05.025 PMID: 26006106
16. Porter JB, Hoyes KP, Abeysinghe RD, Brooks PN, Huehns ER, Hider RC (1991) Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice. Blood. 78(10):2727-34. PMID: 1824264
17. Berdoukas V, Bentley P, Frost H, Schnebli HP (1993) Toxicity of oral iron chelator L1. Lancet. 341 (8852):1088
18. Li W, Garringer HJ, Goodwin CB, Richine B, Acton A, VanDuyn N, et al. (2015) Systemic and cerebral iron homeostasis in ferritin knock-out mice. PLoS One. 10(1):e0117435. doi: 10.1371/journal.pone.0117435 PMID: 25629408
19. Barbeito AG, Levade T, Delisle MB, Ghetti B, Vidal R (2010) Abnormal iron metabolism in fibroblasts from a patient with the neurodegenerative disease hereditary ferritinopathy. Mol. Neurodegener. 5, 50. doi: 10.1186/1750-1326-5-50 PMID: 21067605
20. Moon SN, Han JW, Hwang HS, Kim MJ, Lee SJ, Lee JY, et al. (2011) Establishment of secondary iron overloaded mouse model: evaluation of cardiac function and analysis according to iron concentration. Pediatr Cardiol. 32(7):947-52. doi: 10.1007/s00246-011-0019-4 PMID: 21656238
21. Yatmark P, Morales NP, Chaisri U, Wichaiyo S, Hemstapat W, Srichairatanakool S, et al. (2014) Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone. Exp Toxicol Pathol. 66(7):333-43. doi: 10.1016/j.etp.2014.03.002 PMID: 24907196
22. Ganz T (2013) Systemic iron homeostasis. Physiol Rev. 93(4):1721-41. doi: 10.1152/physrev.00008.2013 PMID: 24137020
23. Benarroch EE (2009) Brain iron homeostasis and neurodegenerative disease. Neurology. 72 (16):1436-40. doi: 10.1212/WNL.0b013e3181a26b30 PMID: 19380704
24. Galanello R (2007) Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag. 3(5):795-805. PMID: 18473004
25. Hider RC, Roy S, Ma YM, Le Kong X, Preston J (2011) The potential application of iron chelators for the treatment of neurodegenerative diseases. Metallomics. 3(3):239-49. doi: 10.1039/c0mt00087f PMID: 21344071
26. Cossu G, Abbruzzese G, Matta G, Murgia D, Melis M, Ricchi V, et al. (2014) Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up. Parkinsonism Relat Disord. 20(6):651-4. doi: 10.1016/j.parkreldis.2014.03.002 PMID: 24661465
27. Capoccia S, Maccarinelli F, Buffoli B, Rodella LF, Cremona O, Arosio P, et al. (2015) Behavioral characterization of mouse models of neuroferritinopathy. PLoS One. 10(2):e0118990. doi: 10.1371/journal.pone.0118990 PMID: 25689865